Health Condition 1: H401- Open-angle glaucoma
Conditions
Interventions
Intervention1: Nanodropper-mediated Microdrops of netarsudil: The nanodropper adaptor would be fit onto a eye drop bottle of Netarsudil which decreases the drop size. This would be given to the patien
Sponsors
Nanodropper, Inc
Eligibility
Inclusion criteria
Inclusion criteria: More than 18 years old Diagnosed with open angle glaucoma or ocular hypertension Have not used netarsudil previously Have not changed IOP-lowering medications within the six weeks preceding enrollment Current IOP exceeds target IOP and netarsudil is deemed appropriate as an adjunctive or next-line therapy Use one another (aside from netarsudil) IOP-lowering topical ophthalmic medication like latanoprost Central corneal thickness less than 620 m Ability to correctly instill eyedrops Adherent to current eyedrops treatment regimen as assessed with screening questionnaire IOP measured in-office is between 20 and 33 mmHg and requires additional IOP-lowering medication
Exclusion criteria
Exclusion criteria: History of angle closure or narrow iridocorneal angles (including previous peripheral iridotomy) and other ocular comorbidities Monocular patients Diagnosis of systemic disease aside from diabetes or hypertension (without retinopathy) that may interfere with study participation Have previously used netarsudil or other ROCK inhibitor like ripasudil Use more than 1 other IOP-lowering topical ophthalmics Use topical or systemic steroids, beta blockers, or alpha agonists Central corneal thickness greater than 620 m or less than 490 m Uncontrolled intraocular pressure (IOP), defined as IOP greater than 33 mm Hg and or or as determined by the treating clinician Recent incisional eye surgery or laser procedures within six months of enrollment Inability to correctly instill eyedrops
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraocular pressure (IOP)Timepoint: 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Self-reported incidence and severity of adverse eventsTimepoint: 6 weeks;Cornea and Contact Lens Research Unit (CCLRU) scaleTimepoint: 6 weeks;Corneal fluorescein staining (CFS) scoreTimepoint: 6 weeks;Ocular Surface Disease Index (OSDI) ScoreTimepoint: 6 weeks | — |
Countries
India
Contacts
Public ContactAnnamalai O
Aravind Eye Hospital
Outcome results
None listed